-
Mashup Score: 7Prevalence and spectrum of pathogenic variants among patients with multiple primary cancers evaluated by clinical characteristics - 2 year(s) ago
Among patients with multiple primary cancers, the prevalence of germline pathogenic variants (PVs) in actionable cancer genes increases with the number of primary cancers (PCs): 13.1% with 2 PCs, 15….
Source: American Cancer Society JournalsCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Clinical Research Job: Regulatory Coordinator II - GI Oncology at Dana-Farber Cancer Institute in 450 Brookline Ave, Boston, MA - 3 year(s) ago
Regulatory Coordinator II – GI Oncology job
Source: careers.dana-farber.orgCategories: Latest Headlines, Oncologists2Tweet-
Looking for senior and junior regulatory specialists to join our DFCI GI Oncology group and help with our expanding number of investigator-initiated clinical trials. Candidates with experience as a CRC or as a regulatory specialist are encouraged to apply. https://t.co/dseYhk9xgB
-
-
Mashup Score: 8
The findings demonstrate the feasibility of rapid identification of the biologic relevance of somatic mutations, which thus advances clinicians’ ability to make informed treatment decisions.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
@MPishvaian There is a very report of a cholangio pt with an FGFR2 F276C extracellular domain mutation who responded to infigratinib. Whenever I see a mutated cysteine in the extracellular domain, I get suspicious that it will predict FGFRi sensitivity. @MiteshBorad https://t.co/rdeQhBzBhx
-
-
Mashup Score: 8TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma - 3 year(s) ago
ATP-competitive fibroblast growth factor receptor (FGFR) kinase inhibitors, including BGJ398 and Debio 1347, show antitumor activity in patients with intrahepatic cholangiocarcinoma (ICC) harboring activating FGFR2 gene fusions. Unfortunately, acquired resistance develops and is often associated with the emergence of secondary FGFR2 kinase domain mutations. Here, we report that the irreversible…
Source: Cancer DiscoveryCategories: Hem/Oncs, Latest HeadlinesTweet-
Lipika Goyal and Nabeel Bardeesy demonstrated that the irreversible FGFR2 inhibitor futibatinib (TAS-120) can overcome acquired resistance caused by reversible FGFR inhibitors like pemigatinib and infigratinib. https://t.co/xccwuDF5Kg #TumorBoardTuesday (23/n) https://t.co/7N3H33HPdw
-
-
Mashup Score: 2
We conducted next generation DNA sequencing on 335 biliary tract cancers and characterized the genomic landscape by anatomic site within the biliary tree. In addition to frequent FGFR2 fusions among patients with intrahepatic cholangiocarcinoma (IHCC), we identified FGFR2 extracellular domain in-frame deletions (EIDs) in 5 of 178 (2.8%) patients with IHCC, including two patients with FGFR2…
Source: Cancer DiscoveryCategories: Hem/Oncs, Latest HeadlinesTweet-
We observed several patients with FGFR2 extracellular domain in-frame deletions (INDELs) who had substantial responses to FGFR inhibitors. We see FGFR2 INDELs in about 2%-3% of intrahepatic cholangiocarcinoma patients. https://t.co/H2C56AMx7I #TumorBoardTuesday (15/n)
-
-
Mashup Score: 0Functions of FGFR2 corrupted by translocations in intrahepatic cholangiocarcinoma - PubMed - 3 year(s) ago
Cholangiocarcinoma, originating from the biliary duct, represents a subset of liver cancer. With about 8000 new cases of cholangiocarcinoma diagnosed annually in the U.S., these fall into three categories: intrahepatic, peri-hilar, and extrahepatic cholangiocarcinoma. Arising from the epithelium of …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
The #FGFR2 receptor ordinarily becomes activated when its ligand, FGF, promotes its dimerization. FGFR2 translocations cause constitutive FGFR2 activation because the FGFR2 fusion partner has an intracellular dimerization domain. @li_fangda https://t.co/EytsvrZJjH (17/n) https://t.co/IqASTv9hfJ
-
-
Mashup Score: 7Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study - 3 year(s) ago
These data support the therapeutic potential of pemigatinib in previously treated patients with cholangiocarcinoma who have FGFR2 fusions or rearrangements.
Source: The Lancet OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
FGFR2 translocations are present in 15% of intrahepatic cholangiocarcinomas. A major milestone was the FDA approval of FGFR inhibitors in cholangiocarcinoma. The first FGFRi approved was pemigatinib. @gaboualfa @miteshborad @doccatenacci https://t.co/jxHi6czZix (12/n)
-
-
Mashup Score: 8Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma - PubMed - 3 year(s) ago
Purpose No standard treatment exists for patients with cholangiocarcinoma for whom first-line gemcitabine-based therapy fails. Fibroblast growth factor receptor 2 ( FGFR2) fusions/translocations are present in 13% to 17% of intrahepatic cholangiocarcinomas. BGJ398, an orally bioavailable, selective …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
A few weeks ago, a 2nd FGFR inhibitor, Infigratinib (BGJ398), was FDA approved for patients with cholangiocarcinoma harboring an FGFR2 translocation. @JavleMilind @rachnatshroff @MiteshBorad @DrElkhoueiry @GABOUALFA @GIcancerDoc https://t.co/3gkw9jRPiN #TumorBoardTuesday (13/n)
-
-
Mashup Score: 6
Original Article from The New England Journal of Medicine — Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Source: New England Journal of MedicineCategories: Hem/Oncs, Latest HeadlinesTweet-
The patient was treated with first-line Gemcitabine/Cisplatin based on data from the ABC-02 trial. https://t.co/v7I2dUxRQk #TumorBoardTuesday (5/n)
-
-
Mashup Score: 6Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers - 3 year(s) ago
This open-label, single-arm, phase 2 clinical trial evaluates whether nab-paclitaxel plus gemcitabine-cisplatin prolongs survival vs that for historical populations treated with gemcitabine-cisplatin alone among patients with advanced biliary tract cancers.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet-
We are eagerly awaiting the results of the phase 3 SWOG 1815 trial evaluating gemcitabine/cisplatin/nab-paclitaxel. The phase 2 trial of this combination was promising. @rachnatshroff @JavleMilind @GIcancerDoc @kmody29 https://t.co/5ITNNQLYQ7 via @JAMAOnc part of @JAMANetwork 6/n
-
Data from this paper really drives home the point that patients w/ multiple cancers are a unique population. Pathogenic germline mutations were found in 13% of pts w/ 2 cancers and 18% of pts w/ 4 cancers. Germline screening is clearly needed in these pts. https://t.co/dN1o36qsla https://t.co/IStIX8NkGX